Zoetis/$ZTS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
- Ticker
- $ZTS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 14,500
- Headquarters
- Parsippany, United States
- Website
- www.zoetis.com
Zoetis Metrics
BasicAdvanced
$33B
13.01
$6.13
0.73
$2.09
2.66%
Price and volume
Market cap
$33B
Beta
0.73
52-week high
$144.83
52-week low
$68.77
Average daily volume
3.9M
Dividend rate
$2.09
Financial strength
Current ratio
3.084
Quick ratio
1.575
Long term debt to equity
2.94
Total debt to equity
2.94
Dividend payout ratio (TTM)
33.71%
Interest coverage (TTM)
15.25%
Profitability
EBITDA (TTM)
4,067
Gross margin (TTM)
71.75%
Net profit margin (TTM)
27.69%
Operating margin (TTM)
38.12%
Effective tax rate (TTM)
20.07%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
15.36%
Return on equity (TTM)
64.91%
Valuation
Price to earnings (TTM)
13.007
Price to revenue (TTM)
3.601
Price to book
10.49
Price to tangible book (TTM)
-61.03
Price to free cash flow (TTM)
14.81
Free cash flow yield (TTM)
6.75%
Free cash flow per share (TTM)
5.383
Dividend yield (TTM)
2.62%
Forward dividend yield
2.66%
Growth
Revenue change (TTM)
1.58%
Earnings per share change (TTM)
6.23%
3-year revenue growth (CAGR)
5.03%
10-year revenue growth (CAGR)
6.96%
3-year earnings per share growth (CAGR)
8.90%
10-year earnings per share growth (CAGR)
16.92%
3-year dividend per share growth (CAGR)
13.74%
10-year dividend per share growth (CAGR)
19.19%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Analyst projections of the future price of Zoetis stock.
Bulls say / Bears say
International sales provide a counterweight to US weakness: second-quarter revenue grew 6% organically, with international companion-animal sales up 5%. (Zoetis)
Livestock offers a separate source of resilience: US livestock revenue rose 23% in the second quarter, supported by cattle and poultry, while international livestock sales grew 6% organically. (Zoetis)
New long-acting osteoarthritis treatments Lenivia and Portela have begun launching in Canada and Europe and contributed to international sales. Their dosing can provide up to three months of pain relief, giving Zoetis a way to broaden treatment use. (Zoetis)
New rivals and heavier discounting are pressuring dermatology and parasiticides, while generic competition and lower Librela sales add further strain on key products. (Zoetis)
A proposed securities class action alleges that Zoetis misled investors about competition and safety concerns affecting core pet products. The allegations are unproven, but the case adds legal and disclosure risk. (Bloomberg Law)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Upcoming events
Zoetis News
AllArticlesVideos
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Business Wire2 weeks ago
Zoetis Declares Fourth Quarter 2026 Dividend
Business Wire3 weeks ago
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Business Wire1 month ago
Funds containing Zoetis
AllUSDEURGBP
Fund name | Fund size | $ZTS weighting |
|---|---|---|
VanEck Morningstar Wide Moat$MOAT | $396M | 1.94% |
VanEck Morningstar Wide Moat€GMVM | $376M | 1.94% |
VanEck Morningstar Wide Moat£MOGB | $376M | 1.94% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.77% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.77% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.